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Abstract Glucocorticoids (GC) induce programmed cell death 
(apoptosis) in immature lymphocytes and are an essential 
component in the therapy of acute lymphatic leukemia. The 
mechanism underlying GC-induced apoptosis particularly in 
leukemia cells is, however, not well understood. Most forms of 
apoptosis seem to employ a common final effector pathway 
characterized by specific proteolytic events mediated by inter-
leukin 1 ß-converting enzyme (ICE) and/or other ICE-like 
cysteine proteases. These events may result in the morphologic 
changes characteristic of apoptosis. To determine whether a 
similar proteolytic pathway is activated during GC-induced 
leukemia cell apoptosis, we investigated poly(ADP-ribose) 
polymerase (PARP), a typical target of ICE-like proteases, 
during GC-induced apoptosis of the human acute T-cell leukemic 
cell line CEM-C7H2. Our studies showed proteolytic PARP 
cleavage suggestive of activation of ICE-like proteases that 
preceeded morphologic signs of apoptosis. We further established 
stably transfected CEM-C7H2 sublines expressing the cowpox 
virus protein CrmA that inhibits some, but not all, ICE-like 
proteases. GC-induced PARP cleavage and apoptosis were 
neither inhibited nor delayed in crmA-expressing cell lines. In 
contrast, crmA expression rendered the same lines resistant to 
Apol/Fas-induced PARP cleavage and apoptosis. Thus, different 
proteases might be activated during the effector phases of GC-
and Apol/Fas-induced apoptosis in human leukemia cells. 
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1. Introduction 
Genetic dissection of programmed cell death in the nema-
tode Caenorhabditis elegans (C. elegans) led to the discovery 
of two essential cell death effector genes, ced-3 and ced-4 [1]. 
While the function of ced-4 remains to be elucidated, ced-3 
has been identified as a C. elegans homolog of the human 
interleukin 1 ß-converting enzyme (ICE), a cysteine protease 
that generates the cytokine IL-lß and plays a key role in 
initiation of immune responses [2]. Subsequent analyses have 
shown that ICE, when overexpressed in appropriate cell types, 
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can induce cell death with the morphologic characteristics of 
apoptosis [3]. However, ICE itself may not be the only pro-
tease important in apoptosis, since ICE-deficient mice are de-
fective in Apol/Fas-induced apoptosis while other forms of 
programmed cell death proceed unimpaired [4,5]. Meanwhile, 
several ICE-homologous cysteine proteases were cloned in-
cluding mouse Nedd2 [6] and its human homolog Ich-1 [7], 
TX/Ich-2/ICErelII [8-10], ICErelIII/TY [9,11], CPP32/Apo-
pain/Yama/Scal [12-16], Mch2 [17], Mch3/Sca2/ICE-LAP3 
[18-20], and Mch4 and 5 [21]. Structural and functional anal-
ysis of ICE suggested that these proteases are tetramers of two 
small heterodimers, require an aspartic acid at the PI position 
of the substrate's cleavage site and, although differing in sub-
strate specificities, induce apoptosis when expressed in their 
active form in eukaryotic cells. Some of these proteases, like 
ICE, are activated by autocatalysis, while others, such as 
CPP32 and Mch-2, might require additional (ICE-like) pro-
teases for activation [22]. Active ICE proteases cleave a vari-
ety of cellular proteins, which may then lead to the character-
istic features of apoptosis [23]. 
One of the targets of ICE-proteases during apoptosis is 
poly(ADP-ribose) polymerase (PARP), also termed poly-
(ADP) ribosyl transferase (ADPRT), a nuclear enzyme that 
is activated by DNA strand breaks [24,25]. In addition to its 
protective action on the genome (predominantly in response 
to environmental stress [26]), it influences polyADP-ribosyla-
tion of nucleases implicated in internucleosomal DNA degra-
dation [27] and consumes NAD and its precursor ATP [28], 
an energy source required for apoptosis [29]. Due to these 
various effects, PARP and its degradation may both contrib-
ute to, or interfere with, the apoptotic process [30,31]. Apop-
totic inactivation of PARP involves a single cleavage of the 
polypeptide after aspartate 216 [12], which separates the N-
terminal Zn-fmger DNA-binding domain from the C-terminal 
automodification and polyADP-ribosylating domains. This re-
sults in liberation of an 85 kDa fragment from the 113 kDa 
full-length enzyme. PARP cleavage is mediated by CPP32 
[12,14,15], Mch-2 [17], and perhaps other members of this 
family, and can be regarded a typical indicator for activation 
of ICE-like proteases. 
The study of ICE-like proteases has been greatly facilitated 
by the discovery of virus proteins that specifically inactivate 
such enzymes, thereby preventing apoptosis of the host cell 
(reviewed in [32]). One of them, the cowpox virus serpin 
CrmA, inactivates some members of the ICE family, like 
ICE itself [33], but not, or to a lesser extent, others, e.g., 
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CPP32/apopain [15]. Hence, it can be used conveniently to 
distinguish ICE-like proteases in different forms of apoptosis. 
In agreement with data from mice made deficient for ICE by 
homologous recombination, crmA overexpression led to in-
hibition of Apol /Fas- induced apoptosis [34]. Moreover, in 
different in vitro cell culture systems, crmA overexpression 
prevented apoptosis induced by neuronal growth factor with-
drawal [35], tumor necrosis factor [36,37] and granzyme B 
[38]. 
Glucocorticoids (GC) induce programmed cell death (apop-
tosis) in various cells of the lymphoid lineage, including thy-
mocytes and lymphatic leukemic cells [39,40]. The mechanisms 
underlying GC-induced apoptosis are poorly understood and 
may differ in various cell types and species. Thus, in rodent 
thymocytes, G C apoptosis is macromolecule neosynthesis-de-
pendent [40,41], employs a Ca2 +-act ivated endonuclease [42], 
and occurs in the absence of functional ICE, as shown in 
corresponding knock-out mice [4]. In human leukemic cells, 
in contrast, GC-induced cell death may occur via transrepres-
sion rather than transactivation [43], and D N A fragmentation 
is mediated by a Ca 2 +- independent endonuclease [44]. A pos-
sible requirement for ICE or other related proteases in G C -
induced leukemic cell death has not been investigated. 
In this study, we report that G C treatment of CEM-C7H2 
acute T-cell leukemic cells, like treatment with antibodies to 
the death inducer membrane protein A p o l / F a s [45,46], results 
in the cleavage of P A R P in a pattern reminiscent of ICE-like 
proteases followed by extensive apoptosis. However, in con-
trast to Apol /Fas- induced P A R P cleavage and apoptosis, 
which were almost completely inhibited by overexpression of 
the cowpox virus protein CrmA, these phenomena essentially 
proceeded unaltered in GC-treated and crm^-overexpressing 
CEM-C7H2 sublines. Our data suggest that GC-induced 
apoptosis in human leukemic cells is associated with, and 
perhaps mediated by, the activation of ICE-like proteases 
that are, however, distinct from ICE itself or other CrmA-
inhibitable ICE family members. 
bated in triplicate with [3H]thymidine for a 6 h pulse, and the uptake 
counted by liquid scintillation. To estimate the degree of apoptosis, 
cells were lysed with Triton X-100, stained with propidium iodide, and 
fluorescence determined by flow cytometry. To study signaling 
through Apol/Fas, 2X105 cells/ml were cultured with 0.5 ug/ml 
mouse monoclonal IgM antibody to Apol/Fas (Immunotech, Mar-
seille, France; clone CH11) or an isotype-matched control monoclo-
nal for 6 h, and the cells processed as described above for GC-treated 
cells. 
2.4. PARP assay 
Cell pellets containing 5 X105 cells were resuspended in 50 ixl of gel 
loading buffer and subjected to ultrasonic treatment with a microtip 
3 times for 10 s to break down high molecular weight DNA. Aliquots 
(20 ul) were separated in the presence of SDS in 0.75-mm-thick poly-
acrylamide gels containing 10% (w/v) acrylamide. Samples were elec-
trophoretically transferred to nitrocellulose at 4°C at 40 V/120 mA for 
6-12 h in a buffer containing 20% methanol, 17 mM Tris-HCl, 170 
mM glycine and 0.02% (w/v) SDS. All further steps were carried out 
at room temperature. Remaining protein binding sites were saturated 
by 5% (w/v) powdered nonfat milk in TBS (20 mM Tris-HCl, 150 mM 
NaCl, pH 7.5) for 1 h. The sheets were incubated with polyclonal 
affinity-purified goat antibodies against human PARP for 6-12 h in 
TBS, washed 3 times with TBS/5% milk and incubated with alkaline 
phosphatase-labeled donkey antibodies against goat IgG. The filters 
were washed 3 times with TBS/5% milk, once with TBS, and the 
alkaline phosphatase activity was detecetd by the color reaction 
with nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolyl phos-
phate. 
2. Materials and methods 
2.1. Cell culture 
The GC-sensitive cell line CEM-C7H2 [47], a subclone of the CEM-
C7 [48], and the GC-resistant cell line CEM-C1 [49] have been de-
scribed previously. All cell lines were grown in 5% C0 2 , saturated 
humidity, at 37°C in RPMI-1640 supplemented with 10% bovine 
calf serum (HyClone, Logan, UT), 100 U/ml penicillin, 100 Ug/ml 
streptomycin, and 2 mM L-glutamine. 
2.2. Stable transfections 
Logarithmically growing CEM-C7H2 cells were washed in PBS, 
pelleted at 300Xg and resuspended at a density of 1 X 107 cells/400 
ul PBS. Cells were mixed with 20 ug of plasmid pHD1.2 (chicken ß-
actin promoter driven crmA expression vector, kindly provided by V. 
Gagliardini) [35], incubated for 10 min on ice, and electroporated with 
the eletroporator (Biorad Lab., Vienna, Austria) set at 960 uF, and 
300 V. After electroporation, cells were again placed on ice for 10 
min, diluted in 20 ml of growth medium and seeded on 96-well flat-
bottom plates. Seletion of stably transfected cells was initiated 48 h 
after electroporation using 1 mg/ml G418 (bioactivity 70%). G418-
resistant clones were cultured and frozen in liquid nitrogen for further 
analyses. 
2.3. Proliferation and apoptosis assay 
Proliferation and apoptosis were determined as previously detailed 
[47]. Briefly, 2.5 X 105 cells/ml were cultured in the presence or absence 
of 1X 10~7 M dexamethasone in 24-well flat-bottom plates for 24, 48, 
and 72 h. For determination of proliferation, cell aliquots were incu-
Fig. 1. PARP is cleaved during GC-induced apoptosis. GC-sensitive 
CEM-C7H2 (A) and GC-resistant CEM-C1 (B) cells were treated 
with 0.1 uM dexamethasone for the indicated time and cellular ex-
tracts subjected to Western analysis with a specific rabbit antiserum 
to PARP. An 85 kDa PARP-fragment, typical for cleavage by ICE-
like proteases, is produced in GC-sensitive CEM-C7H2, but not in 
GC-resistant GR expressing, CEM-C1 cells. 
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3. Results 
To determine whether ICE-like proteases might be activated 
in, and perhaps contribute to, the effector phase of GC-in-
duced apoptosis in leukemic cells, we analyzed cleavage of 
PARP, a typical target of such proteases, during GC treat-
ment. As shown in Fig. 1A, incubation of GC-sensitive CEM-
C7H2 cells with 0.1 uM dexamethasone caused significant 
digestion of the 113 kDa PARP starting at about 28 h after 
treatment initiation. Hence, PARP cleavage preceeded apop-
tosis which generally occurred, after 48-72 h of incubation 
(examplified in Fig. 3A). In contrast, in CEM-C1 cells, that 
express low levels of functional GR but are resistant to GC-
induced apoptosis [50], PARP remained intact over the entire 
observation period (Fig. IB) suggesting that PARP digestion 
may be specifically associated with apoptosis rather than rep-
Fig. 3. CrmA does not prevent GC-induced PARP cleavage and 
apoptosis. Parental CEM-C7H2 and crm^-transfected CEM-C7H2 
sublines 2E8, 2G10, and 2H10 were treated with 0.1 uM dexame-
thasone for 48 h and subjected to apoptosis determination by 
FACS (A) or Western blotting analysis with an antiserum to PARP 
(B). Dexamethasone treatment induced significant apoptosis (hypo-
diploidic cells within the marker window Ml after 48 h) both in the 
parental CEM-C7H2 and crra^-transfected cells (A). In both cell 
types, apoptosis was associated with PARP cleavage (B). Shown are 
the results obtained with CEM-C7H2.2E8 cells, the other 2 cell lines 
gave essentially identical results. The percentages of apoptotic cells 
were 4% (untreated C7H2), 60% (dex-treated C7H2), 4% (untreated 
C7H2.2E8), and 75% (dex-treated C7H2.2E8) in the experiment 
shown. 
Fig. 2. Apol/Fas-induced PARP cleavage and apoptosis are pre-
vented by crmA overexpression. Parental CEM-C7H2 and crmA-
transfected CEM-C7H2 sublines 2E8, 2G10, and 2H10 were treated 
with a monoclonal antibody to Apol/Fas for 6 h and subjected to 
apoptosis determination by FACS (A) or Western blotting analysis 
with an antiserum to PARP (B). Anti-Apol/Fas treatment induced 
apoptosis (hypodiploidic cells within the marker window Ml) in 
about 60% of the parental CEM-C7H2 cells that was reduced al-
most to background levels by crmA overexpression (A). Apoptosis 
in CEM-C7H2 was associated with PARP cleavage (B, lane 2) that 
was markedly suppressed by crmA overexpression (B, lane 4). 
Shown are the results obtained with CEM-C7H2.2E8 cells, the other 
2 cell lines gave essentially identical results. The percentages of 
apoptotic cells were 12% (untreated C7H2), 61% (anti-fas-treated 
C7H2), 11% (untreated C7H2.2E8), and 21% (anti-fas-treated 
C7H2.2E8) in the experiment shown. 
resenting an epiphenomenon of GC treatment. The cleavage 
pattern of PARP observed in CEM-C7H2 was indistinguish-
able from that seen after PARP digestion with prICE/CPP32 
in other systems [12,14] strongly suggesting activation of 
CPP32 or another ICE-like protease in the course of GC-
induced apoptosis. 
Since ICE and some presumably ICE-dependent forms of 
apoptosis can be inhibited by overexpression of the cowpox 
virus protein CrmA [33], we generated CEM-C7H2 cell lines 
stably transfected with the crmA expression vector pHD1.2. 
Several G418-resistant cell lines were established that ex-
pressed crmA as judged by RNA dot-blot analysis. To ascer-
tain that functional relevant levels of CrmA protein were ex-
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pressed, we treated parental CEM-C7H2 and the crmA ex-
pressing CEM-C7H2 sublines 2E8, 2G10, and 2H10 with a 
monoclonal antibody to Apol/Fas. As exemplified in Fig. 2, 
this treatment induced rapid apoptosis and PARP-cleavage in 
the parental CEM-C7H2 line, however, the sublines 2E8, 
2G10, and 2H10 were protected by the overexpression of 
crmA. This confirmed and extended previous reports that 
Apol/Fas induced apoptosis is inhibitable by CrmA 
[34,36,51], and clearly showed that the stably transfected cell 
lines expressed functional CrmA in amounts sufficient to in-
terfere with the cell death pathway. 
CEM-C7H2 and the «-»^-expressing cell lines 2E8, 2G10 
and 2H10 were then treated with 0.1 \iM dexamethasone and 
assayed for apoptosis and PARP cleavage (Fig. 3). Neither 
GC sensitivity, as determined by fiowcytometric DNA content 
analysis, nor degree of PARP cleavage, assayed by Western 
analyses, were reduced in the cr»k4-expressing cell lines com-
pared to the parental CEM-C7H2. Thus, the data strongly 
suggested that GC-induced PARP cleavage and apoptosis oc-
curred independent of expression of CrmA-inhibitable pro-
teases. 
4. Discussion 
The induction of apoptosis in immature lymphocytes by 
GC, which underlies their successful application in the treat-
ment of acute lymphoblastic leukemia, is not well understood. 
After binding to, and activation of, their cytoplasmic recep-
tors, GC seem to induce apoptosis in leukemia cells mainly by 
down-regulation of gene expression as suggested by the ob-
servations that a transactivation-compromised, but transre-
pression-intact, GR mutant (LS7) still mediates GC-induced 
apoptosis [43]. Little, however, is known about the nature of 
the repressed molecules that may be either survival proteins or 
repressors of death-inducers. 
Since ICE and ICE-like proteases have been implicated in 
the effector phase of various forms of apoptosis, including 
that triggered by antibodies to the Apol/Fas membrane pro-
tein (see Section 1), we decided to investigate the role of such 
enzymes in GC-induced leukemia cell death by analyzing 
PARP, a typical substrate for some members (e.g., CPP32 
and Mch-2) of the ICE family [12,14,17]. This study showed 
that, like in GC-induced rat thymocyte apoptosis [28], PARP 
is digested at the onset of GC- as well as Apol/Fas-induced 
apoptosis in our cell system. However, while PARP cleavage 
and apoptosis following anti-Apol/Fas treatment was abro-
gated by overexpression of the cowpox virus ICE inhibitor 
CrmA, these phenomena, when evoked in the same cells by 
GC, were neither prevented nor even delayed by CrmA. This 
suggested that different proteases might be activated during 
Apol/Fas and GC-induced apoptosis. 
While our data clearly documented that different proteases 
operate during Apol/Fas- and GC-mediated apoptosis, they 
could not exactly define the proteases activated because the 
specificity of CrmA is not precisely known. CrmA inhibits 
ICE, and ICE deficient mice are unable to mount Apol/ 
Fas-induced apoptosis [5], making this enzyme the likely 
CrmA target responsible for Apol/Fas apoptosis in our sys-
tem as well. However, ICE itself does not cleave PARP (ex-
cept at very high concentrations [52]) but may rather activate 
downstream ICE-like proteases (e.g., CPP32) that, in turn, 
pass the signal further on in a cascade-like fashion [22,23]. 
The GC-induced death signal apparently bypasses ICE and 
either directly activates the largely CrmA-resistant, PARP-
cleaving CPP32/apopain [15] or another CrmA-resistant pro-
tease that might digest PARP or act upstream thereof. This 
conclusion is in agreement with the observation that GC-in-
duced thymocyte apoptosis proceeds essentially unaltered in 
ICE knockout mice [4,5]. The exact proteases activated in the 
effector phase of GC-induced leukemia cell apoptosis and the 
mechanism leading to their activation remain to be elucidated. 
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